Physician profile
Antoine E Mitri
NPI 1215945530
$42,764.41
in general payments reported to CMS, 2019-2025
64 companies · $7,772 in 2025
The $7,772 reported for 2025 was more than what 88% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,326 · 2020: $4,051 · 2021: $6,515 · 2022: $6,828 · 2023: $6,390 · 2024: $6,882 · 2025: $7,772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $20K · Education: $540 · Travel and Lodging: $398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $20,106.99 |
| Education | $539.85 |
| Travel and Lodging | $397.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $4,263.52 | 2019-2025 | Briviact, Fintepla, Rystiggo |
| Livanova USA, INC. | $4,173.35 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Teva Pharmaceuticals USA, INC. | $3,575.61 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $3,355.65 | 2021-2025 | |
| Sk Life Science, INC. | $2,637.66 | 2020-2025 | Xcopri |
| Novartis Pharmaceuticals Corporation | $2,362.04 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $1,576.22 | 2019-2025 | Ingrezza |
| Biogen, INC. | $1,550.21 | 2019-2025 | Vumerity, Tysabri, Plegridy |
| Emd Serono, INC. | $1,507.13 | 2019-2025 | Mavenclad, Mavenclad |
| Sunovion Pharmaceuticals INC. | $1,289.46 | 2019-2022 | |
| Eisai INC. | $1,197.72 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $1,191.45 | 2019-2025 | Ultomiris, Soliris |
| Amneal Pharmaceuticals LLC | $991.54 | 2019-2025 | Crexont, Rytary |
| Acorda Therapeutics, INC | $935.26 | 2019-2023 | Inbrija |
| Allergan, INC. | $922.23 | 2019-2020 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antoine Mitri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.